The impact of acute myocardial ischemia on the ventricular defibrillation threshold during chronic oral azimilide therapy

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 6, 2007, Pages 629-632

  Chevalier, Philippe ^a   Dubieff, Alexis Durand ^a   Piqueras, Eric ^a   Pineau, Julien ^a   Rivard, Léna ^a   Morel, Elodie ^a   Bui Xan, Bernard ^b   Timour, Quadiri ^b  

^a LOUIS PRADEL HOSPITAL   (France)

^b C H U Laboratoire de Pharmacologie   (France)

Author keywords

Azimilide; Defibrillation; Ischemia; QT interval; Ventricular defibrillation

Indexed keywords

AZIMILIDE; KETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOGENIC SHOCK; CONTROLLED STUDY; DEFIBRILLATION; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; LONG TERM CARE; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; QT INTERVAL; SWINE; TREATMENT DURATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; IMIDAZOLIDINES; LONG QT SYNDROME; MALE; MYOCARDIAL ISCHEMIA; PIPERAZINES; SWINE; VENTRICULAR FIBRILLATION;

EID: 37349039724     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318150d3f5     Document Type: Article

References (31)

1. Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride (NE-10064). Cardiovasc Drug Rev. 1997;15:137-156.
2. Karam R, Marcello S, Brooks RR, et al. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol. 1998;81:40D-46D.
3. Brooks RR, Finch SL. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs. Arzneimittelforschung. 2000;50:597-605.
4. Pratt CM, Singh SN, Al-Khalidi HR, et al, ALIVE Investigators. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol. 2004;43:1211-1216.
5. Hot AT, Pai SM, Timothy P, et al. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2005;28:647-653.
6. Brode SE, Schwartzman D, Callans DJ, et al. ICD-antiarrhythmic drug and ICD-pacemaker interactions. J Cardiovasc Electrophysiol. 1997;8:830-842.
7. Dorian P, Borggrefe M, Al-Khalidi HR, et al. SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable defibrillator. Circulation. 2004;100:3646-3654.
8. Vanoli E, Hull SS, Adamson PB, et al. Prolongation of repolarisation by Ikr and Iks blockade in the prevention of ischaemic ventricular fibrillation after myocardial infarction. Eur Heart J. 1997;18(Suppl):192-P1154.
9. Swindle MM, Smith AC. Comparative anatomy and physiology of the pig. Scand Lab Anim Sci. 1998;25(Suppl 1):1-10.
10. Bazett HC. An analysis of the time relations of electrocardiograms. Heart. 1920;7:353-370.
11. Dorian P, Fain ES, Davy JM, et al. Effect of quinidine and bretylium on defibrillation energy requirements. Am Heart J. 1986;112:19-25.
12. Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J. 1987;114:8-17.
13. Frame LH. The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs. Pacing Clin Electrophysiol. 1989;12:339-346.
14. Jung W, Manz M, Pizzulli L, et al. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992;70:1023-1027.
15. Mehdirad AA, Carnes CA, Nelson SD. The influence of specific and nonspecific potassium current blockade on the defibrillation energy requirement of biphasic shock.15. Pacing Clin Electrophysiol. 1999;22:147-151.
16. Wang M, Dorian P. Dl and d-sotalol decrease defibrillation energy requirements.16. Pacing Clin Electrophysiol. 1989;12:1522-1529.
17. Hohnloser H, Dorian P, Roberts R, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006;114:104-109.
18. Dorian P, Newman D, Sheahan R, et al. d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy. J Cardiovasc Electrophysiol. 1996;7:952-961.
19. Qi X.Q, Newman D, Dorian P. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J Interv Card Electrophysiol. 1999;3:61-67.
20. Carnes CA, Mehdirad AA. Effects of azimilide, acidemia, and the combination on defibrillation energy requirements. J Cardiovasc Pharmacol. 2000;36:283-287.
21. Arredondo MT, Guillen SG, Quinteiro RA. Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions. Eur J Pharmacol. 1986;125:23-28.
22. Opthof T, Misier AR, Coronel R, et al. Dispersion of refractoriness in canine ventricular myocardium. Effects of sympathetic stimulation. Circ Res. 1991;68:1204-1215.
23. Misier AR, Opthof T, van Hemel NM, et al. Dispersion of "refractoriness" in noninfarcted myocardium of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Circulation. 1995;91:2566-2572.
24. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol. 1993;22:810-818.
25. Tovar OH, Bransford PP, Jones JL. Probability of induction and stabilization of ventricular fibrillation with epinephrine. J Mol Cell Cardiol. 1998;30:373-382.
26. Wang M, Dorian P, Ogilvie RI. Isoproterenol increases defibrillation energy requirements in pigs. J Cardiovasc Pharmacol. 1992;19:201-208.
27. Sager PT. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol. 2000;15:41-53.
28. Woosley RL. New antiarrhythmic drugs. In: Zipes DP, ed. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: WB Saunders; 2000:939-943.
29. Dorian P, Wang M, David I, et al. Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model. Circulation. 1991;83:614-621.
30. Murakawa Y, Yamashita T, Kanese Y, et al. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation. J Am Coll Cardiol. 1997;29:688-692.
31. Corey A, Al-Khalidi H, Brezovic C, et al. Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Biopharm Drug Dispos. 1999; 20:59-68.